HCM
MTNB icon

Highbridge Capital Management’s Matinas BioPharma MTNB Stock Holding History

Highbridge Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-128,956
Closed -$457K – 308
2024
Q3 		$457K Sell
128,956
-83,931
-39% -$534K 0.01% 136
2024
Q2 		$1.68M Buy
+212,887
New +$1.93M 0.05% 96

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Highbridge Capital Management's MTNB Position: Q4 2024 in Review

Highbridge Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2024, closing a stake of 128,956 shares — an estimated $457K sold.

Highbridge Capital Management first reported a position in MTNB in Q2 2024 and held it in 2 quarters. The position peaked at $1.68M in Q2 2024. 22 funds tracked by Wall St. Rank hold MTNB as of Q4 2024.

  • Highbridge Capital Management reported no remaining Matinas BioPharma position as of Q4 2024 after selling out during the quarter.
  • Highbridge Capital Management sold 128,956 Matinas BioPharma shares in Q4 2024, an estimated $457K.
  • Highbridge Capital Management first reported a position in Matinas BioPharma in Q2 2024 and held it in 2 quarters.
  • Highbridge Capital Management's Matinas BioPharma position peaked at $1.68M in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2024.

Based on Highbridge Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.